Targeting paclitaxel to the pancreas with a biodegradable drug-eluting device | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Feeds:: Posts; Comments

« AI and IoT Among Disruptive Enterprise Technologies to Watch

Hyaluronidase treatment of high HA pancreatic cancer increased progression-free survival »

Targeting paclitaxel to the pancreas with a biodegradable drug-eluting device

July 3, 2016 by 2012pharmaceutical

Targeting paclitaxel to the pancreas with a biodegradable drug-eluting device

Author: David Orchard-Webb, PhD

Posted in CANCER BIOLOGY & Innovations in Cancer Therapy | Leave a Comment

Leave a Reply Cancel reply

Follow Blog via Email

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 2,657 other subscribers

Email Address
Recent Posts
- Artificial Intelligence and Machine Learning (AI/ML) – Enabled Medical Devices September 26, 2021
- NCCN Shares Latest Expert Recommendations for Prostate Cancer in Spanish and Portuguese September 14, 2021
- Standard Operating Procedures for Updating the Map of LPBI India August 24, 2021
- New avenues for research in membrane biology reveals the mobility of protein at work August 23, 2021
- Can the Public Benefit Company Structure Save US Healthcare? August 20, 2021
- Patients with type 2 diabetes may soon receive artificial pancreas and a smartphone app assistance August 13, 2021
- CNS immune interface August 9, 2021
- 3D printing: Improvising the Next-generation Batteries August 8, 2021
- Novartis uses a ‘dimmer switch’ medication to fine-tune gene therapy candidates August 7, 2021
- LPBI Group announces 5th Academic INTERNSHIP as a Verifiable Certificate in Financial Modeling & Econometrics as One Semester or as One Year Program open to Undergraduate and MBA students August 7, 2021
Archives
Archives
Categories
Categories
Meta

%d bloggers like this: